Matthew C Hernandez1, John R Bergquist1, Jennifer L Leiting1, Tommy Ivanics2, Lin Yang3, Rory L Smoot1, David M Nagorney1, Mark J Truty4. 1. Section of Hepatobiliary and Pancreatic Surgery, Division of Subspecialty General Surgery, Department of Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA. 2. Department of Surgery, Henry Ford Medical Center, Detroit, MI, USA. 3. Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA. 4. Section of Hepatobiliary and Pancreatic Surgery, Division of Subspecialty General Surgery, Department of Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA. truty.mark@mayo.edu.
Abstract
BACKGROUND: Patient-derived xenografts (PDX) are clinically relevant human cancer models that can be used to guide individualized medicine. We aimed to generate PDX models from clinically obtained biopsy specimens (surgical or image-guided) hypothesizing that low volume biopsy specimens could provide sufficient viable tissue to successfully engraft PDX models from patients with unresectable or metastatic disease. MATERIALS AND METHODS: We maintain a prospective high volume gastrointestinal malignancy PDX program. With informed consent and institutional approval, biopsy specimens (surgical or image-guided) were obtained from patients with unresectable or metastatic tumors: pancreatic adenocarcinoma (PDAC), cholangiocarcinoma, gastric and gallbladder carcinoma. Biopsies were implanted into immunodeficient mice. Tumor growth was monitored, viable tumor was passed into subsequent generations, and histopathology was confirmed. RESULTS: In this study, biopsy specimens from 29 patients were used for PDX engraftment. Successful PDX engraftment was variable with highest engraftment rates in gastric and gallbladder carcinoma specimens (100%) compared to engraftment rates of 33% and 29% in PDAC and cholangiocarcinoma respectively. PDX models created from metastasis biopsies compared to unresectable primary tumor tissue demonstrated higher engraftment rates (69% versus 15.4%, p = 0.001). PDX models demonstrated higher engraftment rates when biopsies were obtained during surgical operations (n = 15) compared to image-guided (n = 14) (73% versus 14%, p = 0.003). Patient age, pretreatment status, or ischemic time was not different between biopsy methods. CONCLUSIONS: PDX models can be successfully created from clinical biopsy specimens in patients with metastatic or unresectable GI cancers. The use of clinical biopsy specimens for PDX engraftment can expand the repertoire of stage-specific PDX models for downstream basic/translational research.
BACKGROUND:Patient-derived xenografts (PDX) are clinically relevant humancancer models that can be used to guide individualized medicine. We aimed to generate PDX models from clinically obtained biopsy specimens (surgical or image-guided) hypothesizing that low volume biopsy specimens could provide sufficient viable tissue to successfully engraft PDX models from patients with unresectable or metastatic disease. MATERIALS AND METHODS: We maintain a prospective high volume gastrointestinal malignancyPDX program. With informed consent and institutional approval, biopsy specimens (surgical or image-guided) were obtained from patients with unresectable or metastatic tumors: pancreatic adenocarcinoma (PDAC), cholangiocarcinoma, gastric and gallbladder carcinoma. Biopsies were implanted into immunodeficient mice. Tumor growth was monitored, viable tumor was passed into subsequent generations, and histopathology was confirmed. RESULTS: In this study, biopsy specimens from 29 patients were used for PDX engraftment. Successful PDX engraftment was variable with highest engraftment rates in gastric and gallbladder carcinoma specimens (100%) compared to engraftment rates of 33% and 29% in PDAC and cholangiocarcinoma respectively. PDX models created from metastasis biopsies compared to unresectable primary tumor tissue demonstrated higher engraftment rates (69% versus 15.4%, p = 0.001). PDX models demonstrated higher engraftment rates when biopsies were obtained during surgical operations (n = 15) compared to image-guided (n = 14) (73% versus 14%, p = 0.003). Patient age, pretreatment status, or ischemic time was not different between biopsy methods. CONCLUSIONS:PDX models can be successfully created from clinical biopsy specimens in patients with metastatic or unresectable GI cancers. The use of clinical biopsy specimens for PDX engraftment can expand the repertoire of stage-specific PDX models for downstream basic/translational research.
Authors: Isabel Puig; Irene Chicote; Stephan P Tenbaum; Oriol Arqués; José Raúl Herance; Juan D Gispert; José Jimenez; Stefania Landolfi; Karina Caci; Helena Allende; Leire Mendizabal; Debora Moreno; Ramón Charco; Eloy Espín; Aleix Prat; Maria Elena Elez; Guillem Argilés; Ana Vivancos; Josep Tabernero; Santiago Rojas; Héctor G Palmer Journal: Clin Cancer Res Date: 2013-10-29 Impact factor: 12.531
Authors: John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt Journal: Nat Rev Clin Oncol Date: 2012-04-17 Impact factor: 66.675
Authors: Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff Journal: PLoS Med Date: 2010-04-20 Impact factor: 11.069
Authors: Shahid A Khan; Simon D Taylor-Robinson; Mireille B Toledano; Angus Beck; Paul Elliott; Howard C Thomas Journal: J Hepatol Date: 2002-12 Impact factor: 25.083
Authors: Stephen J Murphy; Steven N Hart; Joema Felipe Lima; Benjamin R Kipp; Mitchell Klebig; Jennifer L Winters; Csilla Szabo; Lizhi Zhang; Bruce W Eckloff; Gloria M Petersen; Steven E Scherer; Richard A Gibbs; Robert R McWilliams; George Vasmatzis; Fergus J Couch Journal: Gastroenterology Date: 2013-08-02 Impact factor: 22.682
Authors: J I Johnson; S Decker; D Zaharevitz; L V Rubinstein; J M Venditti; S Schepartz; S Kalyandrug; M Christian; S Arbuck; M Hollingshead; E A Sausville Journal: Br J Cancer Date: 2001-05-18 Impact factor: 7.640
Authors: Jennifer L Leiting; Stephen J Murphy; John R Bergquist; Matthew C Hernandez; Tommy Ivanics; Amro M Abdelrahman; Lin Yang; Isaac Lynch; James B Smadbeck; Sean P Cleary; David M Nagorney; Michael S Torbenson; Rondell P Graham; Lewis R Roberts; Gregory J Gores; Rory L Smoot; Mark J Truty Journal: JHEP Rep Date: 2020-01-16
Authors: Sarah K Hakuno; Ellis Michiels; Eleonore B Kuhlemaijer; Ilse Rooman; Lukas J A C Hawinkels; Marije Slingerland Journal: Int J Mol Sci Date: 2022-03-15 Impact factor: 5.923